4 Health Services Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 81 points (-0.5%) at 15,762 as of Thursday, Dec. 12, 2013, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,157 issues advancing vs. 1,771 declining with 147 unchanged.

The Health Services industry currently sits down 0.4% versus the S&P 500, which is down 0.2%. A company within the industry that increased today was Boston Scientific ( BSX), up 1.3%. On the negative front, top decliners within the industry include Community Health Systems ( CYH), down 2.9%, Mindray Medical International Limited ADR r ( MR), down 2.6%, Catamaran ( CTRX), down 1.4%, Varian Medical Systems ( VAR), down 1.3% and Aetna ( AET), down 0.8%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. WuXi PharmaTech (Cayman ( WX) is one of the companies pushing the Health Services industry higher today. As of noon trading, WuXi PharmaTech (Cayman is up $0.94 (3.0%) to $32.16 on average volume. Thus far, 304,179 shares of WuXi PharmaTech (Cayman exchanged hands as compared to its average daily volume of 540,700 shares. The stock has ranged in price between $31.33-$32.57 after having opened the day at $31.43 as compared to the previous trading day's close of $31.22.

Wuxi PharmaTech (Cayman) Inc., through its subsidiaries, operates as a pharmaceutical, biotechnology, and medical device research and development outsourcing company in China and the United States. It operates in two segments, Laboratory Services and Manufacturing Services. WuXi PharmaTech (Cayman has a market cap of $2.4 billion and is part of the health care sector. The company has a P/E ratio of 22.6, above the S&P 500 P/E ratio of 17.7. Shares are up 98.2% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate WuXi PharmaTech (Cayman a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates WuXi PharmaTech (Cayman as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full WuXi PharmaTech (Cayman Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, DexCom ( DXCM) is up $1.52 (4.5%) to $35.08 on average volume. Thus far, 467,911 shares of DexCom exchanged hands as compared to its average daily volume of 632,700 shares. The stock has ranged in price between $33.63-$35.08 after having opened the day at $33.93 as compared to the previous trading day's close of $33.56.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems. DexCom has a market cap of $2.4 billion and is part of the health care sector. Shares are up 146.9% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate DexCom a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates DexCom as a sell. The area that we feel has been the company's primary weakness has been its disappointing return on equity. Get the full DexCom Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Waters Corporation ( WAT) is up $0.90 (0.9%) to $96.15 on light volume. Thus far, 160,972 shares of Waters Corporation exchanged hands as compared to its average daily volume of 448,600 shares. The stock has ranged in price between $95.11-$96.17 after having opened the day at $95.25 as compared to the previous trading day's close of $95.25.

Waters Corporation operates as an analytical instrument manufacturer in the United States and internationally. Waters Corporation has a market cap of $8.3 billion and is part of the technology sector. The company has a P/E ratio of 17.4, below the S&P 500 P/E ratio of 17.7. Shares are up 9.3% year to date as of the close of trading on Wednesday. Currently there are 4 analysts that rate Waters Corporation a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Waters Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Waters Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, ResMed ( RMD) is up $0.47 (1.0%) to $45.96 on light volume. Thus far, 405,742 shares of ResMed exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $45.35-$47.60 after having opened the day at $45.91 as compared to the previous trading day's close of $45.49.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $6.7 billion and is part of the health care sector. The company has a P/E ratio of 21.9, above the S&P 500 P/E ratio of 17.7. Shares are up 9.4% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate ResMed a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full ResMed Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null